<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; local</title>
	<atom:link href="http://www.tapanray.in/tag/local/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>How Pharma Growth Strategy Now Extends Beyond Human Intelligence</title>
		<link>http://www.tapanray.in/how-pharma-growth-strategy-now-extends-beyond-human-intelligence/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=how-pharma-growth-strategy-now-extends-beyond-human-intelligence</link>
		<comments>http://www.tapanray.in/how-pharma-growth-strategy-now-extends-beyond-human-intelligence/#comments</comments>
		<pubDate>Fri, 08 Dec 2023 06:00:40 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[examples]]></category>
		<category><![CDATA[generative]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Microsoft]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10844</guid>
		<description><![CDATA[That the drug Industry’s growth strategy now extends beyond human intelligence, across the value chain, are being vindicated by several reports, around the world since several years. Illustratively, on September 1, 2019, Novartis and Microsoft announced a multiyear alliance which will leverage data &#8230; <a href="http://www.tapanray.in/how-pharma-growth-strategy-now-extends-beyond-human-intelligence/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/how-pharma-growth-strategy-now-extends-beyond-human-intelligence/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Shifting Pharma Supply Chain Strategy From Global To Local</title>
		<link>http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=shifting-pharma-supply-chain-strategy-from-global-to-local</link>
		<comments>http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/#comments</comments>
		<pubDate>Mon, 08 Jun 2020 00:00:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[lobbyists]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[logistics]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Procurement]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reevaluating]]></category>
		<category><![CDATA[shifting]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[supply-chain]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[top]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[vulnerability]]></category>
		<category><![CDATA[Vulnerable]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10120</guid>
		<description><![CDATA[Alongside large-scale disruptions of many critical industrial operations, Covid-19 global pandemic took the wind out of the sail of pharma supply chain, as well, at the very onset of lockdowns. This happened in many countries around the world, including the &#8230; <a href="http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Price Control in India: When A Local Media Goes Against, A Global CEO Doesn’t</title>
		<link>http://www.tapanray.in/drug-price-control-in-india-when-a-local-media-goes-against-a-global-ceo-doesnt/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-price-control-in-india-when-a-local-media-goes-against-a-global-ceo-doesnt</link>
		<comments>http://www.tapanray.in/drug-price-control-in-india-when-a-local-media-goes-against-a-global-ceo-doesnt/#comments</comments>
		<pubDate>Sun, 13 Nov 2016 23:40:02 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[AIDAN]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[cheapest]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[demonetization]]></category>
		<category><![CDATA[Donald]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Economic Times]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[Editorial]]></category>
		<category><![CDATA[Estate]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[Forty]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[gratification]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trump]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7963</guid>
		<description><![CDATA[‘Variety is the spice of life’, as the good old saying goes. The week, just gone by, was indeed packed with a wide variety of surprises, well encompassing various important areas, some of which are as follows: Effective November 08, &#8230; <a href="http://www.tapanray.in/drug-price-control-in-india-when-a-local-media-goes-against-a-global-ceo-doesnt/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-price-control-in-india-when-a-local-media-goes-against-a-global-ceo-doesnt/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Vaccines Development: Is it Just a Business Based on Fear?</title>
		<link>http://www.tapanray.in/vaccines-development-is-it-just-a-business-based-on-fear/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=vaccines-development-is-it-just-a-business-based-on-fear</link>
		<comments>http://www.tapanray.in/vaccines-development-is-it-just-a-business-based-on-fear/#comments</comments>
		<pubDate>Mon, 26 Aug 2013 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[Buchwald]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Costs]]></category>
		<category><![CDATA[diphtheria]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[enough]]></category>
		<category><![CDATA[Expenses]]></category>
		<category><![CDATA[fear]]></category>
		<category><![CDATA[First]]></category>
		<category><![CDATA[Gates]]></category>
		<category><![CDATA[GAVI]]></category>
		<category><![CDATA[Gerhard]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[JV]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[malaria]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[MSD]]></category>
		<category><![CDATA[NCD]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NIH]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Partnership]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pox]]></category>
		<category><![CDATA[prevention]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[small]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TB]]></category>
		<category><![CDATA[threat]]></category>
		<category><![CDATA[Tuberculosis]]></category>
		<category><![CDATA[vaccination]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3486</guid>
		<description><![CDATA[‘Vaccination – A Business based on fear’, is the title of a book written by Dr. Gerhard Buchwald M.D, a German medical doctor and a vaccination critic. This book talks about: “The damage and the deaths caused by vaccination are written &#8230; <a href="http://www.tapanray.in/vaccines-development-is-it-just-a-business-based-on-fear/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/vaccines-development-is-it-just-a-business-based-on-fear/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patent Conundrum: Ignoring India Will Just Not be Foolhardy, Not An Option Either</title>
		<link>http://www.tapanray.in/patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either</link>
		<comments>http://www.tapanray.in/patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either/#comments</comments>
		<pubDate>Mon, 29 Apr 2013 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[assessment]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[Enticing]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[exit]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[foolhardy]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[FTA]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Grant]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[HTA]]></category>
		<category><![CDATA[infringement]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[investment]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[issue]]></category>
		<category><![CDATA[Lamy]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[lucrative]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[opposition]]></category>
		<category><![CDATA[option]]></category>
		<category><![CDATA[Pascal]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[post]]></category>
		<category><![CDATA[pre]]></category>
		<category><![CDATA[PwC]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[transfer]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[witty]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2267</guid>
		<description><![CDATA[The recent verdict of the Supreme Court against Novartis, upholding the decision of the Indian Patent Office (IPO) against grant of patent to their cancer drug Glivec, based on Section 3(d) of the Indian Patents Act, has caused a flutter &#8230; <a href="http://www.tapanray.in/patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharmaceutical innovation and Public Health Interest: Ways to achieving the dual objectives</title>
		<link>http://www.tapanray.in/pharmaceutical-innovation-and-public-health-interest-ways-to-achieving-the-dual-objectives/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharmaceutical-innovation-and-public-health-interest-ways-to-achieving-the-dual-objectives</link>
		<comments>http://www.tapanray.in/pharmaceutical-innovation-and-public-health-interest-ways-to-achieving-the-dual-objectives/#comments</comments>
		<pubDate>Mon, 06 Feb 2012 00:00:50 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[achieving]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[dual]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[objectives]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Ways]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=137</guid>
		<description><![CDATA[Healthcare industry in general and the pharmaceutical sector in particular have been experiencing  a plethora of innovations not only to cure and effectively manage ailments to improve the quality of life, but also to help increasing overall disease-free life expectancy &#8230; <a href="http://www.tapanray.in/pharmaceutical-innovation-and-public-health-interest-ways-to-achieving-the-dual-objectives/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharmaceutical-innovation-and-public-health-interest-ways-to-achieving-the-dual-objectives/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Social Media – an evolving new-age powerful communication tool for the Pharmaceutical Industry, both global and local</title>
		<link>http://www.tapanray.in/social-media-an-evolving-new-age-powerful-communication-tool-for-the-pharmaceutical-industry-both-global-and-local/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=social-media-an-evolving-new-age-powerful-communication-tool-for-the-pharmaceutical-industry-both-global-and-local</link>
		<comments>http://www.tapanray.in/social-media-an-evolving-new-age-powerful-communication-tool-for-the-pharmaceutical-industry-both-global-and-local/#comments</comments>
		<pubDate>Mon, 20 Dec 2010 01:00:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[an]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[attractiveness]]></category>
		<category><![CDATA[both]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[evolving]]></category>
		<category><![CDATA[Facebook financial]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[new-age]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[powerful]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[tool]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=332</guid>
		<description><![CDATA[David Edelman in his article titled, &#8220;Branding in the Digital Age:You&#8217;re Spending your Money in All the Wrong Places&#8221;, published in the &#8216;Harvard Business Review&#8217;  dated December 2010, commented the following: &#8220;Consumers today connect with brands in fundamentally new ways, often &#8230; <a href="http://www.tapanray.in/social-media-an-evolving-new-age-powerful-communication-tool-for-the-pharmaceutical-industry-both-global-and-local/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/social-media-an-evolving-new-age-powerful-communication-tool-for-the-pharmaceutical-industry-both-global-and-local/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does the Indian Patents Act conform to Article 27 (Patentable Subject Matter) of TRIPS on the issue of ‘local working of patents’?</title>
		<link>http://www.tapanray.in/does-the-indian-patents-act-conform-to-article-27-patentable-subject-matter-of-trips-on-the-issue-of-local-working-of-patents/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-the-indian-patents-act-conform-to-article-27-patentable-subject-matter-of-trips-on-the-issue-of-local-working-of-patents</link>
		<comments>http://www.tapanray.in/does-the-indian-patents-act-conform-to-article-27-patentable-subject-matter-of-trips-on-the-issue-of-local-working-of-patents/#comments</comments>
		<pubDate>Mon, 22 Feb 2010 01:00:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[27]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Article]]></category>
		<category><![CDATA[conform]]></category>
		<category><![CDATA[Does]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[issue]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[Matter]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[on]]></category>
		<category><![CDATA[Patentable]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Subject]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[working]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=464</guid>
		<description><![CDATA[India is one of the signatories of TRIPS and has a national commitment on adherence to this important international agreement. It is, therefore, widely believed that the amended Indian Patents Act will be TRIPS compliant. A recent circular from CGPTD: &#8230; <a href="http://www.tapanray.in/does-the-indian-patents-act-conform-to-article-27-patentable-subject-matter-of-trips-on-the-issue-of-local-working-of-patents/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-the-indian-patents-act-conform-to-article-27-patentable-subject-matter-of-trips-on-the-issue-of-local-working-of-patents/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
